One-Stop Solid Tumor Targeting CAR-T Development Solutions
End‑to‑end solid‑tumor CAR‑T development—from antigen/scFv discovery and CAR optimization to cell engineering, in‑vitro/in‑vivo efficacy, and IND support. Incorporates dual/logic‑gated and armored CARs, plus trafficking and persistence enhancements to overcome the tumor microenvironment and improve safety and translation.
One-Stop Solid Tumor Targeting CAR-T Development Solutions
Receive your quote directly from the manufacturer.
Creative Biolabs provides a dedicated, end‑to‑end path for solid‑tumor CAR‑T development—covering antigen selection, scFv discovery, CAR design/format optimization, vectoring, primary T‑cell engineering, and in‑vitro/in‑vivo efficacy packages tailored to hostile tumor microenvironments.
The program integrates strategies such as dual/logic‑gated CARs, armored CARs (cytokine/chemokine payloads), trafficking and persistence enhancement, and on‑target/off‑tumor risk mitigation to improve safety and clinical translatability.
Key Features / Benefits
- Antigen & epitope assessment for solid tumors; scFv generation and liability screening
- Design options: second/third‑gen, tandem/dual, logic‑gated and switchable CARs
- Microenvironment‑aware optimization (trafficking, persistence, exhaustion resistance)
- Comprehensive release & efficacy testing; IND‑readiness and documentation support
Relevant Applications
- Solid‑tumor programs requiring target validation and CAR format selection
- Preclinical optimization addressing trafficking, persistence and TME suppression
- IND‑enabling efficacy/safety packages for first‑in‑human studies
